Zydus’ Saroglitazar wins FDA priority review after strong Phase 3 results in liver disease trial

The therapy also delivered significant improvements in key liver enzyme markers

Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial

This marks one of the most closely watched oncology readouts at this year’s medical congress

Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial

The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer

Glenmark posts strong FY26 results with 27.5% revenue jump

AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial

The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis

Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial

First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors

Lilly posts strong early clinical results for one-shot gene-editing cholesterol therapy

A one-shot gene-editing cholesterol therapy could soon be a reality

Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook

Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros

Pfizer powers ahead in 2026 with strong Q1 results as pipeline momentum builds

The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook

Lilly posts explosive Q1 2026 results

Lifts full-year outlook as obesity drug boom accelerates